Sonnet BioTherapeutics Holdings Inc. Share Price Today, Forecast Target, Chat & Where To Buy [SONN]

  • Today's Sonnet BioTherapeutics Holdings Inc. share price is 1.26 (as of 16:00 02-Dec-2025) which is a change of -1.84 or -59.35% from the last closing price of 1.26.
  • With 10,456,154 shares traded this gives Sonnet BioTherapeutics Holdings Inc. a market capitalisation of 8,918,092.
  • Sonnet BioTherapeutics Holdings Inc.'s most recent daily high has been 3.23 and daily low 1.26. The Sonnet BioTherapeutics Holdings Inc. share price 52 week high has been 19 and the 52 week low 1.08.
  • Based on the most recent Sonnet BioTherapeutics Holdings Inc. share price opening of 1.26, the current Sonnet BioTherapeutics Holdings Inc. EPS (earnings per share) are -6.73 and the PE (price earnings ratio) is n/a.

Featured Brokers For Buying Sonnet BioTherapeutics Holdings Inc. Shares

It currently costs 1.26 to buy one share in Sonnet BioTherapeutics Holdings Inc. (as of 16:00 02-Dec-2025) which is a change of -1.84 or -59.35% from the last closing price of 3.1. To buy shares in Sonnet BioTherapeutics Holdings Inc. you will need a stock trading platform like City Index.

We have ranked, compared and reviewed some of the best share-dealing platforms and accounts in the UK that are regulated by the Financial Conduct Authority (FCA). The main things to compare when choosing a share dealing account are the costs of buying and selling shares (trading fees) and how much it will cost to keep those shares on your account. You should also compare account types so you have the option to deal shares in a tax-efficient ISA, SIPP or for your children.

Is Sonnet BioTherapeutics Holdings Inc. A Good Investment?

The below Sonnet BioTherapeutics Holdings Inc. share price analysis and market data includes key financials, earnings estimates, peer performance, dividends, news and a company profile that will give you an indication as to whether this stock is a buy, sell or hold. Subscribe to Good Money Guide Analysis for expert opinion on the latest investment opportunities.

Tell us what you think:

Scroll to Top